XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
OTHER (INCOME)/EXPENSE, NET
 9 Months Ended
Sep. 30, 2023
Other Nonoperating Income (Expense) [Abstract]  
Other (Income)/Expense, Net OTHER (INCOME)/EXPENSE, NET
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2023202220232022
Interest expense (Note 10)$280 $299 $850 $938 
Royalty and licensing income (Note 4)(365)(374)(1,068)(967)
Royalty income - divestiture (Note 4)(217)(205)(623)(597)
Equity investment losses (Note 9)— 14 213 966 
Integration expenses (Note 6)54 114 180 343 
Loss on debt redemption (Note 10)— — — 266 
Divestiture gains (Note 4)— — — (211)
Litigation and other settlements
(61)44 (393)32 
Investment income(107)(52)(304)(89)
Provision for restructuring (Note 6)141 17 321 60 
Other17 3 37 52 
Other (income)/expense, net$(258)$(140)$(787)$793 
    
Litigation and Other Settlements

BeiGene Settlement

In August 2023, BMS and BeiGene, Ltd. ("BeiGene") entered into an agreement that settled all on-going disputes and claims between the parties, including those related to the Abraxane license and supply agreements and related arbitration proceedings as further described in "—Note 18. Legal Proceedings and Contingencies".

The agreement also provided for the termination of all contractual relationships between the parties, including the license and supply arrangements pertaining to Revlimid and Vidaza effective as of December 31, 2023, subject to BeiGene’s right to continue to sell all remaining inventory beyond that date. In consideration for the above, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $322 million of expense that was included in Other (income)/expense, net during the three months ended September 30, 2023. The expense was determined based on the closing price of the shares on the date of the transfer. In addition, the remaining BeiGene ordinary shares owned by BMS under the share subscription agreement were converted to American Depository Shares, which were subsequently sold during the three months ended September 30, 2023.

AstraZeneca Settlement

In July 2023, BMS entered into an agreement with AZ to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 18. Legal Proceedings and Contingencies". AZ will pay an aggregate of $560 million to BMS in four payments through September 2026, which will be subject to sharing arrangements with Ono and Dana-Farber. BMS's share is approximately $418 million, of which the net present value of $384 million was reflected in Other (income)/expense during the three months ended September 30, 2023.

Nimbus Change of Control Income

During the nine months ended September 30, 2023, $400 million of income was recorded in Other (income)/expense in connection with Nimbus' TYK2 program change of control provision. Refer to "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information.